SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Giladi Moshe
(Last) (First) (Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115
(Street)
WAYNE PA 19087
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
07/26/2023 		3. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Science Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 7,008 D
Restricted Share Units 6,496(1) D
Restricted Share Units 2,983(2) D
Restricted Share Units 1,653(3) D
Restricted Share Units 154(4) D
Restricted Share Units 353(5) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to buy) 03/02/2024 03/01/2031 Ordinary Shares 1,951(6) $153.09 D
Stock Options (Right to buy) 11/02/2024 11/01/2031 Ordinary Shares 831(7) $107.73 D
Stock Options (Right to buy) 05/03/2024 05/02/2032 Ordinary Shares 7,693(8) $83.77 D
Stock Options (Right to buy) 03/01/2024 02/29/2032 Ordinary Shares 4,346(9) $80.59 D
Stock Options (Right to buy) (10) 11/05/2029 Ordinary Shares 833 $77.49 D
Stock Options (Right to buy) 02/28/2024 02/27/2033 Ordinary Shares 10,804(11) $76.97 D
Stock Options (Right to buy) 03/03/2024 03/02/2030 Ordinary Shares 2,779(12) $69.37 D
Stock Options (Right to buy) (10) 03/21/2029 Ordinary Shares 2,822 $47.04 D
Stock Options (Right to buy) (10) 02/26/2028 Ordinary Shares 3,451 $21.15 D
Stock Options (Right to buy) (10) 02/21/2027 Ordinary Shares 6,875 $7.15 D
Explanation of Responses:
1. Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
2. Represents restricted share units that are scheduled to vest in equal installments on May 3, 2024 and 2025, subject to the reporting person's continued employment through such dates.
3. Represents restricted share units that are scheduled to vest in equal installments on March 1, 2024 and 2025, subject to the reporting person's continued employment through such dates.
4. Represents restricted share units that are scheduled to vest in equal installments on November 2, 2024, subject to the reporting person's continued employment through such date.
5. Represents restricted share units that are scheduled to vest in equal installments on March 2, 2024, subject to the reporting person's continued employment through such date.
6. Options to buy 1,951 ordinary shares, 976 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
7. Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates.
8. Options to buy 7,693 ordinary shares, 1,924 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
9. Options to buy 4,346 ordinary shares, 1,087 shares of which are currently exercisable and the remainder will vest in equal installments on each of March 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
10. Currently exercisable.
11. Options to buy 10,804 ordinary shares will vest in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
12. Options to buy 2,779 ordinary shares, 2,085 shares of which are currently exercisable and the remainder will vest on March 3, 2024, subject to the reporting person's continued employment through such date.
Remarks:
Steven Robbins, as attorney in fact for Giladi, Moshe 12/20/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.